The emergence of multidrug resistance (MDR) was a major obstacle to treating cancer diseases.137 Studies have shown that NF-κB could increase the expression of the MDR1 gene, and then inhibition of NF-κB activity could enhance the sensitivity of drug-resistant cancer cells to chemotherapy drugs.138 Abdin et al. proposed that the combination of NF-κB inhibitors (Pentoxifylline/Bortezomib) and DOX could reduce DOX resistance in breast cancer cells. The gene discussed is ABCB1; the disease is breast carcinoma.